SCHEMBL10088950

SCHEMBL10088950

O=C(O)C1CN(CC2=Cc3ccc(OCc4ccc(C(F)(F)F)cc4)cc3OC2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR5 Q9H228 16/20 0.55
S1PR1 P21453 13/20 0.55
PDGFRA P16234 2/20 0.55
ALOX5 P09917 1/20 0.54
PRKX P51817 2/20 0.51
S1PR4 O95977 2/20 0.51
S1PR3 Q99500 2/20 0.51
IKBKE Q14164 1/20 0.51
PIM1 P11309 1/20 0.50
PRKD3 O94806 1/20 0.50
CDK7 P50613 1/20 0.50
JAK3 P52333 1/20 0.50
TNK2 Q07912 1/20 0.50
ACVR1 Q04771 1/20 0.48
MAOA P21397 2/20 0.46
MAOB P27338 2/20 0.46
HTR2A P28223 1/20 0.46
KCNH2 Q12809 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
HRH3 Q9Y5N1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10088685 0.88 S1PR5 (0.55) S1PR5S1PR1PDGFRAPRKXS1PR4
SCHEMBL10088680 0.88 S1PR5 (0.56) S1PR5S1PR1PDGFRAALOX5PRKX
SCHEMBL12441169 0.88 S1PR5 (0.49) S1PR5S1PR1PDGFRAALOX5PRKX
SCHEMBL10088993 0.88 S1PR5 (0.50) S1PR5S1PR1PDGFRAALOX5PRKX
SCHEMBL10088998 0.87 S1PR5 (0.51) S1PR5S1PR1PDGFRAALOX5PRKX
SCHEMBL10088970 0.87 S1PR5 (0.55) S1PR5S1PR1PDGFRAPRKXS1PR4
SCHEMBL10088698 0.86 S1PR5 (0.52) S1PR5S1PR1PDGFRAPRKXS1PR4
SCHEMBL10088693 0.85 S1PR5 (0.48) S1PR5S1PR1PDGFRAPRKXS1PR4
SCHEMBL12440576 0.84 ALOX5 (0.52) ALOX5MAOAMAOBKCNH2HRH3
SCHEMBL10089072 0.84 S1PR5 (0.53) S1PR5S1PR1PDGFRAS1PR4S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2354134-B1 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR ASTELLAS PHARMA INC (JP) 2016-02-24 EP disclosed
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2012-07-12 US disclosed
US-8193378-B2 2H-chromene compound and derivative thereof ASTELLAS PHARMA INC. (JP) 2012-06-05 US disclosed
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed
WO-2010064707-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF アステラス製薬株式会社 (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, CCR1 S1PR5 4/4885S1PR1 1/4885PDGFRA 380/4885
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, S1PR4 S1PR5 7/4885S1PR1 1/4885PDGFRA 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.